Results 261 to 270 of about 119,519 (336)

Latest Research Hot Spots of Atopic Dermatitis Management Using Janus Kinase Inhibitor: A Bibliometric Analysis and Visualized Review. [PDF]

Clin Cosmet Investig Dermatol
Nukaly H, AlHuraish DS, Bakhamees BH, AlHemli HA, Alsaadoon MS, Alhejji RK, Alotaibi G, Alomran SA, AlHalees Z.   +8 more
europepmc   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source

Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. [PDF]

Rheumatology (Oxford)
Källmark H, Gullstrand B, Kahn F, Grenmyr E, Kahn R, Einarsson JT, Bengtsson AA, Kapetanovic MC.   +7 more
europepmc   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Response to letter regarding 'Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis'. [PDF]

Ann Med
Yang H, An T, Zhang Q.
europepmc   +1 more source

Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis [PDF]

Daud Manzar, Nikhil Nair, Emmanuel Suntres, Myanca Rodrigues, Mohannad Abu‐Hilal   +4 more
openalex   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Janus kinase inhibitors in localized scleroderma: a systematic literature review. [PDF]

Turk J Med Sci
Şener S, Şener YZ, Batu ED, Sari A, Akdoğan A.   +4 more
europepmc   +1 more source

Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data [PDF]

Emi Sato, Naoko Obonai, Mayuko Iwata, Kotaro Ito, Shinichi Imafuku   +4 more
openalex   +1 more source